8.49
price down icon5.35%   -0.48
after-market After Hours: 8.52 0.03 +0.35%
loading
Bicycle Therapeutics Plc Adr stock is traded at $8.49, with a volume of 458.26K. It is down -5.35% in the last 24 hours and down -22.61% over the past month. Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
See More
Previous Close:
$8.97
Open:
$8.72
24h Volume:
458.26K
Relative Volume:
1.49
Market Cap:
$592.37M
Revenue:
$36.90M
Net Income/Loss:
$-166.28M
P/E Ratio:
-2.5805
EPS:
-3.29
Net Cash Flow:
$-203.53M
1W Performance:
-7.72%
1M Performance:
-22.61%
6M Performance:
-62.48%
1Y Performance:
-65.90%
1-Day Range:
Value
$8.20
$8.90
1-Week Range:
Value
$8.20
$9.69
52-Week Range:
Value
$8.20
$28.67

Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile

Name
Name
Bicycle Therapeutics Plc Adr
Name
Phone
011441223261503
Name
Address
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Name
Employee
305
Name
Twitter
@Bicycle_tx
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
BCYC's Discussions on Twitter

Compare BCYC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BCYC
Bicycle Therapeutics Plc Adr
8.49 592.37M 36.90M -166.28M -203.53M -3.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-08-24 Initiated Stephens Equal-Weight
Sep-06-24 Initiated RBC Capital Mkts Outperform
Aug-07-24 Downgrade B. Riley Securities Buy → Neutral
Sep-11-23 Upgrade B. Riley Securities Neutral → Buy
Aug-31-22 Initiated Cowen Outperform
Jul-28-22 Initiated Barclays Overweight
Jul-06-22 Resumed Canaccord Genuity Buy
Apr-13-22 Downgrade B. Riley Securities Buy → Neutral
Apr-07-22 Resumed Cantor Fitzgerald Overweight
Feb-14-22 Initiated Morgan Stanley Equal-Weight
Dec-17-21 Initiated SVB Leerink Outperform
Dec-09-21 Initiated Needham Buy
Sep-30-21 Initiated B. Riley Securities Buy
Apr-20-21 Initiated JMP Securities Mkt Outperform
Oct-12-20 Initiated Cantor Fitzgerald Overweight
Jun-12-20 Initiated Oppenheimer Outperform
Apr-17-20 Initiated H.C. Wainwright Buy
Nov-14-19 Initiated ROTH Capital Buy
Sep-11-19 Upgrade Goldman Neutral → Buy
Jun-17-19 Initiated Canaccord Genuity Buy
Jun-17-19 Initiated Goldman Neutral
Jun-17-19 Initiated Jefferies Buy
Jun-17-19 Initiated Piper Jaffray Overweight
View All

Bicycle Therapeutics Plc Adr Stock (BCYC) Latest News

pulisher
Mar 27, 2025

Bicycle Therapeutics reshuffles leadership, aims for oncology advances By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Bicycle Therapeutics reshuffles leadership, aims for oncology advances - Investing.com India

Mar 27, 2025
pulisher
Mar 24, 2025

Bicycle Therapeutics stock hits 52-week low at $8.98 By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 12, 2025

Bicycle Therapeutics’ SWOT analysis: innovative platform drives stock potential - Investing.com India

Mar 12, 2025
pulisher
Mar 03, 2025

Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.

Mar 03, 2025
pulisher
Feb 25, 2025

Jefferies cuts Bicycle Therapeutics price target to $42 from $53 By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Bicycle Therapeutics stock holds $33 target, Buy rating at Rodman By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Mizuho maintains Harmony Biosciences $42 target, Outperform rating - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

Mizuho maintains Harmony Biosciences $42 target, Outperform rating By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Jan 15, 2025

Bicycle Therapeutics' SWOT analysis: platform potential drives stock outlook - Investing.com India

Jan 15, 2025
pulisher
Jan 13, 2025

Bicycle Therapeutics reports promising cancer drug trial results - Investing.com India

Jan 13, 2025
pulisher
Jan 07, 2025

Bicycle therapeutics CDO Santiago Arroyo sells shares worth $69,646 - Investing.com India

Jan 07, 2025
pulisher
Jan 06, 2025

Bicycle Therapeutics CFO Alethia Young sells shares totaling $19,655 - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

Bicycle Therapeutics exec sells $30k in shares - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares By Investing.com - Investing.com South Africa

Jan 06, 2025
pulisher
Jan 06, 2025

Bicycle Therapeutics CTO sells shares worth $60,119 By Investing.com - Investing.com South Africa

Jan 06, 2025
pulisher
Jan 06, 2025

Bicycle Therapeutics CAO Travis Thompson sells $67,292 in shares - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

Bicycle Therapeutics CEO Lee sells shares worth $172,952 By Investing.com - Investing.com South Africa

Jan 06, 2025
pulisher
Jan 06, 2025

Bicycle Therapeutics CEO Lee sells shares worth $172,952 - Investing.com India

Jan 06, 2025
pulisher
Dec 19, 2024

Bicycle Therapeutics' SWOT analysis: stock outlook amid clinical trials and cash strength - Investing.com India

Dec 19, 2024
pulisher
Dec 14, 2024

Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data By Investing.com - Investing.com South Africa

Dec 14, 2024
pulisher
Dec 14, 2024

Bicycle Therapeutics' SWOT analysis: stock's potential rides on clinical data - Investing.com

Dec 14, 2024
pulisher
Dec 09, 2024

FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - Yahoo Finance

Dec 09, 2024
pulisher
Nov 27, 2024

ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study - Yahoo Finance

Nov 27, 2024
pulisher
Nov 25, 2024

Pharmacovigilance and Drug Safety Software Market Size to Reach USD 371.88 Million by 2032, Growing at a 6.76% CAGR – SNS Insider - Yahoo Finance

Nov 25, 2024
pulisher
Nov 21, 2024

SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study - Yahoo Finance

Nov 21, 2024
pulisher
Nov 19, 2024

ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance

Nov 19, 2024
pulisher
Nov 15, 2024

Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy - Yahoo Finance

Nov 15, 2024
pulisher
Nov 13, 2024

Bicycle Therapeutics' SWOT analysis: innovative platform fuels stock's potential - Investing.com India

Nov 13, 2024
pulisher
Nov 13, 2024

Bicycle Therapeutics' chief accounting officer sells shares worth $157,113 - Investing.com

Nov 13, 2024
pulisher
Nov 02, 2024

Bicycle Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 02, 2024
pulisher
Oct 31, 2024

Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - Yahoo Finance

Oct 31, 2024
pulisher
Oct 28, 2024

Bicycle Therapeutics' SWOT analysis: stock's potential rides on innovative platform - Investing.com India

Oct 28, 2024
pulisher
Oct 24, 2024

Bicycle Therapeutics retains stock target and Buy rating on promising data - Investing.com

Oct 24, 2024
pulisher
Oct 23, 2024

Bicycle Therapeutics spotlights cancer treatment targets - Investing.com

Oct 23, 2024
pulisher
Oct 21, 2024

Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance

Oct 21, 2024
pulisher
Oct 19, 2024

Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? - MSN

Oct 19, 2024
pulisher
Oct 14, 2024

A company insider recently sold 3,212 shares of Bicycle Therapeutics Plc ADR [BCYC]. Should You also Consider to Sale? – Knox Daily - Knox Daily

Oct 14, 2024
pulisher
Oct 10, 2024

BCYC’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Oct 10, 2024
pulisher
Oct 08, 2024

Keeping an Eye on Bicycle Therapeutics Plc ADR (BCYC) After Insider Trading Activity - Knox Daily

Oct 08, 2024
pulisher
Oct 08, 2024

Bicycle Therapeutics Plc ADR (BCYC)’s stock price range in the last year - US Post News

Oct 08, 2024
pulisher
Oct 05, 2024

Bicycle therapeutics executive sells shares worth over $21k - Investing.com India

Oct 05, 2024
pulisher
Oct 05, 2024

Bicycle therapeutics executive sells shares to cover tax obligations - Investing.com India

Oct 05, 2024
pulisher
Oct 04, 2024

Bicycle therapeutics COO sells shares worth over $21k - Investing.com India

Oct 04, 2024
pulisher
Oct 04, 2024

Bicycle therapeutics CEO sells shares worth over $71k - Investing.com

Oct 04, 2024
pulisher
Oct 04, 2024

Bicycle therapeutics CTO sells shares worth over $21k - Investing.com

Oct 04, 2024
pulisher
Oct 04, 2024

Bicycle therapeutics executive sells shares worth over $5,000 - Investing.com

Oct 04, 2024

Bicycle Therapeutics Plc Adr Stock (BCYC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):